It must be underlined that these remissions persisted through 8 months of follow-up, demonstrating that CD19 CAR-T combined with short-term MMF can effectively reset both B and T cell-mediated pathways in refractory antisynthetase syndrome. This evidence concerns the gene CD19 and antisynthetase syndrome.